Organon & Co. (LON:0A9W)

Market Cap	3.16B
Revenue (ttm)	5.11B
Net Income (ttm)	690.14M
Shares Out	n/a
EPS (ttm)	2.66
PE Ratio	4.57
Forward PE	n/a
Dividend	0.88 (5.69%)
Ex-Dividend Date	Feb 24, 2025

Volume	1,166
Average Volume	2,623
Open	15.63
Previous Close	15.62
Day's Range	15.38 - 15.78
52-Week Range	10.86 - 18.17
Beta	n/a
RSI	50.72
Earnings Date	Feb 14, 2025

About Organon & Co.

Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health in the United States and internationally. Its women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple o...

• Industry: Pharmaceutical Preparations
• Founded: 2020
• Employees: 10,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A9W

Financial Performance

In 2024, Organon & Co.'s revenue was $6.40 billion, an increase of 2.24% compared to the previous year's $6.26 billion. Earnings were $864.00 million, a decrease of -15.54%.

Financial numbers in USD